## Time for full physiology



## ANOCA/MINOCA: from Cinderella to Princess

Filippo Crea
Editor-in-Chief of the European Heart Journal
Ospedale Gemelli Isola – Catholic University





# Transient myocardial ischemia during daily life in patients with syndrome X

Kaski JC, Crea F, Nihoyannopoulos P, Hackett D, Maseri A

Am J Cardiol. 1986 Dec 1;58(13):1242-7




### Pathogenetic uncertainties in SX

Is it a cardiac disease?

- Is microvascular dysfunction present?
- Does myocardial dysfunction cause ischemia?








### Pathogenetic uncertainties in SX

Is it a cardiac disease?

- Is microvascular dysfunction present?
- Does myocardial dysfunction cause ischemia?

## Microvascular dysfunction in SX detected by stress CMR





(Lanza et al, JACC 2008)




### Pathogenetic uncertainties in SX

Is it a cardiac disease?

- Is microvascular dysfunction present?
- Does myocardial dysfunction cause ischemia?


### Consequences of ischemia-reperfusion





(isoprostanes, lipid hydroperoxides, conjugated dienes)

## Myocardial ischemia in SX detected by the release of European Society of Cardiology lipid peroxidation products during stress



(Buffon et al, Am J Physiol 2001)



#### REVIEW ARTICLE

#### Coro

MEDIC

### Coronary Microv

Paolo G. Camici, M

#### Table 1. Clinical Classification of Coronary Microvascular Dysfunction.

Coronary microvascular dysfunction in the absence of obstructive CAD and myocardial diseases This type represents the functional counterpart of traditional coronary risk factors (smoking, hypertension, hyperlipidemia, and diabetes and insulin-resistant states). It can be identified by noninvasive assessment of coronary flow reserve. This type is at least partly reversible, and coronary flow reserve can also be used as a surrogate end point to assess efficacy of treatments aimed at reducing the burden of risk factors.

Coronary microvascular dysfunction in the presence of myocardial diseases This type is sustained in most instances by adverse remodeling of intramural coronary arterioles. It can be identified by invasive or noninvasive assessment of coronary flow reserve and may be severe enough to cause myocardial ischemia. It has independent prognostic value. It remains unclear whether medical treatment may reverse some cases. It is found with primary (genetic) cardiomyopathies (e.g., dilated and hypertrophic) and secondary cardiomyopathies (e.g., hypertensive and valvular).

Coronary microvascular dysfunction in the presence of obstructive CAD This type may occur in the context of either stable CAD or acute coronary syndromes with or without ST-segment elevation and can be sustained by numerous factors. It is more difficult to identify than the first two types and may be identified through the use of an integrated approach that takes into account the clinical context with the use of a combination of invasive and noninvasive techniques. There is some early evidence that specific interventions might prevent it or limit the resultant ischemia.

latrogenic coronary microvascular dysfunction This type occurs after coronary recanalization and seems to be caused primarily by vasoconstriction or distal embolization. It can be identified with the use of either invasive or noninvasive means on the basis of a reduced coronary flow reserve, which seems to revert spontaneously in the weeks after revascularization. Pharmacologic treatment has been shown to promptly restore coronary flow reserve, and it may also change the clinical outcome. The likelihood of distal embolization can be reduced by the use of appropriate devices during high-risk procedures.




# 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)

### 6.1 Microvascular angina

# Obstructive CAD in patients with suspected angina (n=398,978)





Results of Noninvasive Tests

#### CLINICAL RESEARCH


Clinical trials



### Clinical charact patients with m international ar by the Coronary International St

Hiroaki Shimokawa<sup>1,2</sup>\*, Aki


#### **Graphical Abstract**



# Stratified medical therapy using invasive coronary function testing in angina: CORMICA trial

**ESC** 

European Society of Cardiology



(Ford et al, JACC 2018)






European Heart Journal (2020) **41**, 3219–3221 doi:10.1093/eurheartj/ehaa050



### Doctor, I feel microvascular chest pain

### Filippo Crea (1) 1,2\*

<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, and <sup>2</sup>Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Largo A. Gemelli, 8, 00168 Rome, Italy



(Boden et al, JACC 23)

#### **ESC GUIDELINES**

# 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

The diagnosis of MINOCA is made immediately upon coronary angiography in a patient presenting with features consistent with an AMI, as detailed by the following criteria:

- Universal AMI criteria<sup>8</sup>
- (2) Non-obstructive coronary arteries on angiography, defined as no coronary artery stenosis ≥50% in any potential IRA
- (3) No clinically overt specific cause for the acute presentation





## Fourth universal definition of myocardial infarction (2018)

#### New sections

- Takotsubo syndrome.
- MINOCA.
- Chronic kidney disease.
- Atrial fibrillation.
- Regulatory perspective on myocardial infarction.
- Silent or unrecognized myocardial infarction.

### **Causes of MINOCA**



- Epicardial causes
  - Coronary spasm
  - Plaque fissure with positive remodeling
  - Coronary dissection
- Microvascular causes
  - Unstable microvascular angina
  - Takotsubo syndrome
  - Myocarditis
  - Coronary thromboembolism



# Eliminato l'impossibile, ciò che resta, *per quanto improbabile sia*, deve essere la verità

Il segno dei quattro

Sherlock Holmes (Sir Arthur Conan Doyle)